GVHD grade and treatment
Patient no. . | Donor . | Acute GVHD grade . | Chronic GVHD . | Treatment . |
|---|---|---|---|---|
| 1 | Sib | No | Limited | Topical steroids |
| 2 | MUD | III, hepatic/cutaneous | Limited* | Systemic steroids, CsA, infliximab, daclizumab |
| 3 | MUD | II, cutaneous/gut | Limited | Topical steroids |
| 4 | MUD | IV, hepatic/cutaneous | Extensive | Systemic steroids, CsA, ATG |
| 8 | MUD | I, cutaneous | No | Topical steroids |
| 11 | Sib | IV, hepatic/cutaneous/gut | NA | Systemic steroids, CsA, ATG |
| 12 | MUD | IV, hepatic/cutaneous | Extensive | Systemic steroids, CsA, thalidomide |
| 13 | MUD | IV, hepatic/cutaneous/gut | Extensive | Systemic steroids, MMF, ATG |
| 14 | Sib | IV, hepatic/cutaneous/gut | Extensive | Systemic steroids, CsA |
| 21 | MUD | III, hepatic/cutaneous | Extensive | Systemic steroids, CsA |
| 23 | Sib | III, cutaneous/gut | Extensive | Systemic steroids, CsA, azathioprine, thalidomide |
| 24 | Sib | IV, hepatic/cutaneous | NA | Systemic steroids, CsA, ATG |
| 25 | Sib | III, gut | NA | Systemic steroids, CsA, ATG |
| 29 | Sib | I, cutaneous | Limited | Topical steroids |
| 33 | Sib | I, cutaneous | No | Topical steroids |
| 38 | MUD | I, cutaneous | No | Topical steroids |
| 39 | MUD | I, cutaneous | No | Topical steroids |
| 46 | MUD | IV, hepatic/cutaneous/gut | NA | Systemic steroids, CsA, ATG |
Patient no. . | Donor . | Acute GVHD grade . | Chronic GVHD . | Treatment . |
|---|---|---|---|---|
| 1 | Sib | No | Limited | Topical steroids |
| 2 | MUD | III, hepatic/cutaneous | Limited* | Systemic steroids, CsA, infliximab, daclizumab |
| 3 | MUD | II, cutaneous/gut | Limited | Topical steroids |
| 4 | MUD | IV, hepatic/cutaneous | Extensive | Systemic steroids, CsA, ATG |
| 8 | MUD | I, cutaneous | No | Topical steroids |
| 11 | Sib | IV, hepatic/cutaneous/gut | NA | Systemic steroids, CsA, ATG |
| 12 | MUD | IV, hepatic/cutaneous | Extensive | Systemic steroids, CsA, thalidomide |
| 13 | MUD | IV, hepatic/cutaneous/gut | Extensive | Systemic steroids, MMF, ATG |
| 14 | Sib | IV, hepatic/cutaneous/gut | Extensive | Systemic steroids, CsA |
| 21 | MUD | III, hepatic/cutaneous | Extensive | Systemic steroids, CsA |
| 23 | Sib | III, cutaneous/gut | Extensive | Systemic steroids, CsA, azathioprine, thalidomide |
| 24 | Sib | IV, hepatic/cutaneous | NA | Systemic steroids, CsA, ATG |
| 25 | Sib | III, gut | NA | Systemic steroids, CsA, ATG |
| 29 | Sib | I, cutaneous | Limited | Topical steroids |
| 33 | Sib | I, cutaneous | No | Topical steroids |
| 38 | MUD | I, cutaneous | No | Topical steroids |
| 39 | MUD | I, cutaneous | No | Topical steroids |
| 46 | MUD | IV, hepatic/cutaneous/gut | NA | Systemic steroids, CsA, ATG |
Sib indicates matched sibling donor; NA, not applicable; MMF, mycophenolate mofetil.
Patient no. 2 developed limited chronic GVHD after the initial DLI; following resolution, further dose escalation (3 doses) was associated with development of more severe GVHD.